⏳ Fetching live dividend data...
Home › Calculator › KRTX Dividend Calculator 2026
Karuna Therapeutics, Inc. · NASDAQ
Price: $329.83 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in KRTX → $10.6K in 10 years · $5.34/month
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis. Beyond KarXT, the firm is also advancing a pipeline of other drug candidates that interact with muscarinic receptors. Karuna Therapeutics, Inc. has forged several strategic partnerships, encompassing licensing agreements with Eli Lilly and Company and Zai Lab (Shanghai) Co., Ltd., a patent license with PureTech Health LLC, and drug discovery collaborations with Charles River Laboratories and PsychoGenics, Inc. Established in 2009, the enterprise initially operated under the name Karuna Pharmaceuticals, Inc., before officially adopting its current corporate identity, Karuna Therapeutics, Inc., in March 2019. Its corporate headquarters are located in Boston, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open KRTX position with:
Real after-tax yield depends on where you live and how you hold KRTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.61% | -2.19% | $61 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.52% | -2.28% | $52 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.49% | -2.31% | $49 / yr |
| 🇬🇧 UK ISA | 0% | 0.61% | -2.19% | $61 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.56% | -2.24% | $56 / yr |
| 🇨🇦 TFSA | 0% | 0.61% | -2.19% | $61 / yr |
| 🇨🇦 CA Taxable | 25% | 0.46% | -2.34% | $46 / yr |
| 🇦🇺 Super (pension) | 15% | 0.52% | -2.28% | $52 / yr |
| 🇦🇺 AU Taxable | 30% | 0.43% | -2.37% | $43 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.45% | -2.35% | $45 / yr |
| 🇫🇷 FR Taxable | 30% | 0.43% | -2.37% | $43 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
KRTX pays quarterly — 4 times per year. Next ex-div: TBD.
How KRTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for KRTX sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the KRTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Karuna Therapeutics, Inc. (KRTX) is currently trading at $329.83, trading near its 52-week high. The current dividend yield is 0.61% based on an annual payout of $2.00 per share.
Karuna Therapeutics, Inc. (KRTX) is a healthcare stock currently trading at $329.83 with a dividend yield of 0.61%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever